Clinical trials: HCC - Hepatocellular Carcinoma
Hepatocellular Carcinoma
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or…
- Trial name
- NCT02519348
- Testing
- Tremelimumab, Durvalumab, Bevacizumab
- Where
- 44 sites in United States, China and 7 more
- Volunteers
- 433 people
- Sponsor
- MedImmune LLC
Chronic Hepatitis B
Follow-up Strategy of Chronic Hepatitis B for Early Detection and Diagnosis of Hepatocellular Carcinoma: A Randomized Control Trial
This study is a randomized control prospective study. The aim of this study is to establish an all-round and convenient follow-up strategy of Chronic Hepatitis B for early detection and diagnosis of Hepatocellular Carcinoma…
- Trial name
- NCT02817685
- Testing
- 3 months, 6 months, 3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI
- Where
- China
- Volunteers
- 7,660 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Malignant Glioma, Hepatocellular Carcinoma
Early-Phase Safety of Proton Therapy Equipment
The main purpose of this study is to collect the safety data of Sumitomo Heavy Industries' proton therapy equipment for the treatment of solid cancer patients in Linkou Chang Gung Memorial Hospital, including the patients'…
- Conditions
- Malignant Glioma, Hepatocellular Carcinoma, Head and Neck Malignant Tumor, Prostate Cancer
- Trial name
- NCT02315989
- Testing
- proton therapy
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Chang Gung Memorial Hospital
Advanced Hepatocellular Carcinoma
HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma
This study is conducted in patients with advanced hepatocellular carcinoma (HCC). This study includes three arms: A, B, and C. Arm A will receive HLX07 combination therapy with HLX10 and HLX04 as first line treatment.
- Trial name
- NCT05290220
- Testing
- HLX07, HLX10, HLX04
- Volunteers
- 60 people
- Sponsor
- Shanghai Henlius Biotech
Hepatocellular Carcinoma
A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
Hepatocellular carcinoma (HCC) is a prevalent malignancy with great disease burden both in Taiwan and worldwide 1. Early stage HCC can be treated by surgical resection, radiofrequency ablation, embolization and liver…
- Trial name
- NCT05281926
- Testing
- Poly ICLC
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody compared with transarterial chemoembolization (TACE) for patients with intermediate-stage hepatocellular carcinoma (HCC)…
- Trial name
- NCT03791918
- Testing
- Lenvatinib, PD-1 antibody, TACE
- Where
- 3 sites in China
- Sponsor
- Sun Yat-sen University
HCC - Hepatocellular Carcinoma
Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC
This study is a real-world, single-arm, observational study primarily collecting data on patients with hepatocellular carcinoma who experienced disease progression after receiving lenvatinib in combination with PD-1 inhibitors as…
- Trial name
- Lenalidomide (NCT07184424)
- Testing
- lenalidomide
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Carcinoma, Hepatocellular
Radiofrequency Ablation in Treating Patients With Liver Cancer (Hepatocellular Carcinoma)
This phase II trial studies how effectively radiofrequency ablation prevents recurrence of hepatocellular carcinoma (HCC) in patients with easily removable tumors.
- Trial name
- NCT01669668
- Testing
- radiofrequency ablation, laparoscopy
- Sponsor
- Washington University School of Medicine
Hepatocellular Carcinoma (HCC)
Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma
This is a Phase 2, open-label, single-arm, multicenter study designed to evaluate the safety and efficacy of atezolizumab, bevacizumab, and tocilizumab in patients with locally advanced, metastatic, and/or unresectable…
- Trial name
- AB-TCZ (NCT07774247)
- Testing
- Atezolizumab, Bevacizumab, Tocilizumab
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- CHA University
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
HCC, Therapy Adverse Effect
ICIs With and Without MWA in Advanced Hepatocellular Carcinoma
Immunotherapy has become the main treatment recommendation for HCC. MWA treatment induces peripheral immune response, which may enhance the effectiveness of immunotherapy for advanced HCC.
- Trial name
- IMI-aHCC (NCT06581497)
- Testing
- ICIs, ICIs+MWA
- Where
- China
- Volunteers
- 52 people
- Sponsor
- The First People's Hospital of Neijiang
Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC)
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors.
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer
- Trial name
- NCT07557225
- Testing
- 18F-T2 PET/CT
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Hepatocellular Carcinoma, Liver Transplant
Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
To assess the primary effects and safety of camrelizumab (SHR-1210) plus apatinib for downstaging/bridging of HCC before liver transplantation.
- Trial name
- NCT04035876
- Testing
- Camrelizumab plus apatinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cirrhosis
Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis
The investigators will investigate the usefulness of biannual ultrasonography versus annual non-contrast magnetic resonance imaging for surveillance of hepatocellular carcinoma in single arm patients.
- Trial name
- MAGNUS-HCC (NCT02551250)
- Testing
- annual noncontrast MRI, biannual ultrasonography
- Where
- 6 sites in South Korea
- Volunteers
- 211 people
- Sponsor
- JOON-IL CHOI
Advanced Hepatocellular Carcinoma
Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma
This is a Phase Ib study to evaluate the safety, tolerability and efficacy of Sintilimab combined with IBI305 in patients with advanced hepatocellular carcinoma in China.
- Trial name
- NCT04072679
- Testing
- Sintilimab+IBI305
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese Academy of Medical Sciences
Carcinoma, Hepatocellular
CIK Treatment for HCC Patient Underwent Radical Resection
This is a randomized controlled study. About 200 patients with hepatocellular carcinoma who underwent radical resection will be included.
- Trial name
- NCT01749865
- Testing
- Cytokine-Induced Killer Cells
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
Celebrex and Metformin for Postoperative Hepatocellular Carcinoma
This prospective trial aims to compare the role of celebrex alone, metformin alone, and celebrex plus metformin in preventing HCC recurrence after hepatic resection.
- Trial name
- XBD (NCT03184493)
- Testing
- Celebrex plus Metformin, Celebrex, Metformin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
This project is based on the assumption that the nurse coordinators of the centres have common missions at each of the key stages of patient care.
- Trial name
- INFIC (NCT04209491)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alcoholic Cirrhosis
National Cohort of Uncomplicated Alcoholic Cirrhosis
Hepatocellular carcinoma (HCC) is a major public health problem, whose incidence is increasing in developed countries and is the leading cause of death in patients with cirrhosis.
- Trial name
- CIRRAL (NCT01213927)
- Where
- France
- Volunteers
- 709 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris